$MRVI News

Is Maravai LifeSciences Holdings (MRVI) Priced Too Highly For Its Sales?

Maravai LifeSciences (MRVI) Stock Gets Fair Value Boost On mRNA And CleanCap Optimism

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026

Full Transcript: Maravai LifeSciences Q2 2026 Earnings Call

What Is Maravai’s (MRVI) Comeback Really Worth to Investors?

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

Is Maravai LifeSciences Holdings (MRVI) Cheap If Cash Flow Recovers?

Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In?

UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel

Maravai (MRVI) Q2 2026 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. Q2 2026 Earnings Call Summary

Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript

Maravai LifeSciences Q2 Earnings Call Highlights

Maravai LifeSciences Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation

Maravai Lifesciences (NASDAQ:MRVI) Shares Slide Despite Q2 Beat as Full-Year Revenue Outlook Weighs

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Maravai LifeSciences Affirms FY2026 Sales Guidance of $205.000M-$215.000M vs $210.433M Est